petrelintide

all catalysts(0)

nothing on the calendar yet

News(10)

• 3 takeaways from a European obesity scientific meeting
  Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…
  biopharma_dive · 4h ago
• Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
  Eli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…
  fiercebiotech · 1d ago
• Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
  Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28.
  fiercebiotech · 1d ago
• Roche cuts muscle-sparing obesity drug after mid-stage disappointment
  Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…
  biospace · 2d ago
• Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
  The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmo…
  biospace · 9d ago
• Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
  Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fi…
  fiercebiotech · 1mo ago
• Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
  Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…
  biospace · 1mo ago
• Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
  Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
  biospace · 1mo ago
• Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
  Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.
  fiercebiotech · 1mo ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 1mo ago